RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin

The combination of gemcitabine plus cisplatin (GP) is regarded as a first-line treatment for patients with unresectable or recurrent biliary tract cancer (BTC). Several proteins including human equilibrative nucleoside transporter-1 (hENT1), deoxycytidine kinase (DCK), cytidine deaminase (CDA), and...

Descripción completa

Detalles Bibliográficos
Autores principales: Chun, Jung Won, Lee, Boyoung, Park, Weon Seo, Han, Nayoung, Hong, Eun Kyung, Park, Eun Young, Han, Sung Sik, Park, Sang-Jae, Kim, Tae Hyun, Lee, Woo Jin, Woo, Sang Myung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538709/
https://www.ncbi.nlm.nih.gov/pubmed/34682775
http://dx.doi.org/10.3390/jcm10204652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538709/
https://www.ncbi.nlm.nih.gov/pubmed/34682775
http://dx.doi.org/10.3390/jcm10204652

Ejemplares similares